Intellikine LLC

Infinity Pharmaceuticals, Inc.

Plexxikon Inc.

University of California

Millennium Pharmaceuticals Limited

Itellikine LLC

Takeda Pharmaceutical Company Limited

Katrina Chan

Yi Liu

Pingda Ren

Liansheng Li

Troy Edward Wilson

Alfredo C Castro

Catherine Anne Evans

Daniel A Snyder

Christian Rommel

Martin R Tremblay

Tao Liu

Andre Lescarbeau

Somarajannair Janardanannair

Prabha N Ibrahim

Wayne Spevak

Guoxian Wu

Jack Lin

Simon F Campbell

Ying Zhang

Todd Ewing

Jiazhong Zhang

Songyuan Shi

Marika Nespi

Phuongly Pham

John Buell

Jeffrey Yung Wu

Jeffrey Wu

Kevan M Shokat

Andrew Gaheem Hsieh

Michael Martin

Davide Ruggero

Beth Apsel

Ken Dong

David Fruman

Matthew Janes

David Pearce

Morris Feldman

Simon Fraser Campbell

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Heterocyclic compounds and uses thereof

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

Certain chemical entities, compositions and methods

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z, Z, and Zare as described herein, compositions thereof, and uses thereof.

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Kinase inhibitors and methods of use

Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.

Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity. 

Heterocyclic kinase inhibitors

Substituted isoquinolinone compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Chemical compounds, compositions and methods for kinase modulation

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

Benzothiazole kinase inhibitors and methods of use

Growing community of inventors

Fremont, CA, United States of America

Katrina Chan